Related Experiment Video
Updated: Aug 13, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Insulin detemir: from concept to clinical experience
1School of Clinical Medical Sciences--Diabetes, University of Newcastle upon Tyne, Framlington Place, NE2 4HH, UK. philip.home@newcastle.ac.uk
Expert Opinion on Pharmacotherapy
|February 2, 2006
Summary
Insulin detemir offers improved basal insulin therapy for diabetes, showing comparable glycemic control to NPH insulin with reduced variability and hypoglycemia risk. It also demonstrated a lower propensity for weight gain in clinical trials.
Area of Science:
- Endocrinology
- Pharmacology
- Biotechnology
Background:
- Subcutaneously administered basal insulins previously had high within-person variability.
- Limitations in time-action profiles of older basal insulins impacted diabetes management.
- A need existed for basal insulin with improved pharmacokinetic properties.
Purpose of the Study:
- To evaluate the efficacy and tolerability of insulin detemir as a basal insulin.
- To compare insulin detemir with neutral protamine Hagedorn (NPH) insulin.
- To assess the benefits of an all-analogue insulin regimen.
Main Methods:
- Pharmacological characterization of insulin detemir.
- Phase III clinical trials comparing insulin detemir to NPH insulin.
- Evaluation of an all-analogue regimen (insulin detemir + insulin aspart) versus human insulin regimens.
Main Results:
- Insulin detemir demonstrated glycaemic control comparable to NPH insulin with significantly lower variability.
- Consistent reductions in nocturnal hypoglycaemic events were observed with insulin detemir.
- Insulin detemir was associated with a significantly reduced propensity for weight gain.
- The all-analogue regimen showed superior blood glucose control and reduced hypoglycemia compared to human insulin-based regimens.
Conclusions:
- Insulin detemir provides a valuable basal insulin option with improved efficacy and tolerability.
- Its unique pharmacokinetic profile addresses limitations of previous basal insulins.
- Insulin detemir facilitates treatment regimens offering good clinical outcomes for diabetes management.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...